Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by Whittier Trust Co. of Nevada Inc.

Whittier Trust Co. of Nevada Inc. raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 41,189 shares of the medical research company’s stock after buying an additional 602 shares during the quarter. Whittier Trust Co. of Nevada Inc.’s holdings in Thermo Fisher Scientific were worth $20,495,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Whittier Trust Co. increased its stake in Thermo Fisher Scientific by 1.5% during the first quarter. Whittier Trust Co. now owns 88,940 shares of the medical research company’s stock worth $44,255,000 after purchasing an additional 1,351 shares during the period. ESG Planning DBA Harper Investing increased its stake in Thermo Fisher Scientific by 40.0% during the first quarter. ESG Planning DBA Harper Investing now owns 1,219 shares of the medical research company’s stock worth $607,000 after purchasing an additional 348 shares during the period. Prevail Innovative Wealth Advisors LLC increased its stake in Thermo Fisher Scientific by 1,721.3% during the first quarter. Prevail Innovative Wealth Advisors LLC now owns 7,340 shares of the medical research company’s stock worth $3,652,000 after purchasing an additional 6,937 shares during the period. Cornercap Investment Counsel Inc. purchased a new stake in Thermo Fisher Scientific during the first quarter worth about $1,499,000. Finally, Graybill Wealth Management LTD. purchased a new stake in shares of Thermo Fisher Scientific during the first quarter worth approximately $6,460,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the transaction, the executive vice president owned 23,167 shares in the company, valued at $9,960,188.31. This trade represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.33% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

TMO has been the topic of a number of recent research reports. Stifel Nicolaus cut their target price on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating on the stock in a research note on Thursday, April 24th. Barclays cut their target price on shares of Thermo Fisher Scientific from $475.00 to $450.00 and set an “equal weight” rating on the stock in a research note on Tuesday, June 24th. UBS Group lowered shares of Thermo Fisher Scientific from a “buy” rating to a “neutral” rating and cut their target price for the stock from $500.00 to $460.00 in a research note on Tuesday, July 8th. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Wednesday, May 21st. Finally, Argus cut their price objective on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a “buy” rating on the stock in a report on Tuesday, April 29th. Four investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $600.30.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $425.44 on Tuesday. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $627.88. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77. The business has a fifty day moving average of $409.45 and a two-hundred day moving average of $475.17. The company has a market cap of $160.60 billion, a P/E ratio of 24.95, a price-to-earnings-growth ratio of 2.31 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating analysts’ consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The company had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. During the same quarter last year, the company earned $5.11 earnings per share. Thermo Fisher Scientific’s quarterly revenue was up .2% compared to the same quarter last year. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.40%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.09%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.